
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8523130/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell, 2014, 159, 676-690.	28.9	2,318
2	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. JAMA Oncology, 2016, 2, 1023.	7.1	1,192
3	Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. Journal of Clinical Investigation, 2016, 126, 1052-1066.	8.2	874
4	Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer. New England Journal of Medicine, 2013, 368, 623-632.	27.0	692
5	Mutational Profile of Advanced Primary and Metastatic Radioactive lodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for <i>BRAF, PIK3CA</i> , and <i>AKT1</i> . Cancer Research, 2009, 69, 4885-4893.	0.9	488
6	Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocrine Pathology, 2022, 33, 27-63.	9.0	388
7	Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1562-E1566.	3.6	378
8	Follicular variant of papillary thyroid carcinoma. Cancer, 2006, 107, 1255-1264.	4.1	363
9	Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 1015.	2.2	359
10	Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocrine-Related Cancer, 2008, 15, 1069-1074.	3.1	351
11	Relief of Feedback Inhibition of <i>HER3</i> Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in <i>BRAF</i> -Mutant Thyroid Carcinomas. Cancer Discovery, 2013, 3, 520-533.	9.4	328
12	Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Modern Pathology, 2010, 23, 1191-1200.	5.5	325
13	Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. Journal of Clinical Investigation, 2011, 121, 4700-4711.	8.2	305
14	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nature Medicine, 2019, 25, 767-775.	30.7	282
15	Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules. JAMA Surgery, 2018, 153, 817.	4.3	275
16	Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis. Cancer, 2006, 106, 1286-1295.	4.1	266
17	AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. Cancer Cell, 2015, 27, 533-546.	16.8	263
18	Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell, 2018, 34, 256-270.e5.	16.8	195

#	Article	IF	CITATIONS
19	Histopathologic characterization of radioactive iodineâ€refractory fluorodeoxyglucoseâ€positron emission tomographyâ€positive thyroid carcinoma. Cancer, 2008, 113, 48-56.	4.1	184
20	Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1615-1620.	7.1	183
21	Genomic Dissection of Hurthle Cell Carcinoma Reveals a Unique Class of Thyroid Malignancy. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E962-E972.	3.6	169
22	Vemurafenib Redifferentiation of <i>BRAF</i> Mutant, RAI-Refractory Thyroid Cancers. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1417-1428.	3.6	165
23	Papillary Thyroid Carcinoma Tall Cell Variant. Thyroid, 2008, 18, 1179-1181.	4.5	158
24	Genome-Wide Appraisal of Thyroid Cancer Progression. American Journal of Pathology, 2002, 161, 1549-1556.	3.8	156
25	Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid, 2020, 30, 1505-1517.	4.5	143
26	Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma. Head and Neck, 2016, 38, E1192-9.	2.0	142
27	Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. Cancer, 1996, 78, 10-16.	4.1	141
28	Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma. Endocrine Pathology, 2016, 27, 205-212.	9.0	140
29	Genome-Wide Profiling of Papillary Thyroid Cancer Identifies MUC1 as an Independent Prognostic Marker. Cancer Research, 2004, 64, 3780-3789.	0.9	137
30	Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects. Thyroid, 2019, 29, 311-321.	4.5	135
31	Hürthle Cell Carcinoma: A Critical Histopathologic Appraisal. Journal of Clinical Oncology, 2001, 19, 2616-2625.	1.6	126
32	Encapsulated Papillary Thyroid Carcinoma: A Clinico-Pathologic Study of 106 Cases with Emphasis on Its Morphologic Subtypes (Histologic Growth Pattern). Thyroid, 2009, 19, 119-127.	4.5	125
33	Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules. Annals of Surgical Oncology, 2015, 22, 3996-4001.	1.5	124
34	Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. Human Pathology, 2015, 46, 657-664.	2.0	121
35	Tall Cell Variant of Papillary Thyroid Carcinoma without Extrathyroid Extension: Biologic Behavior and Clinical Implications. Thyroid, 2007, 17, 655-661.	4.5	119
36	Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland. Cancer, 2006, 106, 1669-1676.	4.1	118

RONALD A GHOSSEIN

#	Article	IF	CITATIONS
37	Papillary Thyroid Cancer—Aggressive Variants and Impact on Management: A Narrative Review. Advances in Therapy, 2020, 37, 3112-3128.	2.9	115
38	Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases. Human Pathology, 2010, 41, 927-934.	2.0	109
39	Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid, 2017, 27, 512-517.	4.5	109
40	A Proposal to Redefine Close Surgical Margins in Squamous Cell Carcinoma of the Oral Tongue. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 555.	2.2	109
41	Papillary Thyroid Carcinomas with Cervical Lymph Node Metastases Can Be Stratified into Clinically Relevant Prognostic Categories Using Oncogenic <i>BRAF</i> , the Number of Nodal Metastases, and Extra-Nodal Extension. Thyroid, 2012, 22, 575-584.	4.5	108
42	<i>NF2</i> Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. Cancer Discovery, 2015, 5, 1178-1193.	9.4	107
43	The History of the Follicular Variant of Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 15-22.	3.6	107
44	Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts. Human Pathology, 2015, 46, 26-33.	2.0	103
45	Follicular variant of papillary thyroid carcinoma: Genome-wide appraisal of a controversial entity. Genes Chromosomes and Cancer, 2004, 40, 355-364.	2.8	102
46	Prognostic Implications of Papillary Thyroid Carcinoma with Tall-Cell Features. Thyroid, 2014, 24, 662-670.	4.5	98
47	Adrenocortical Adenoma and Carcinoma: Histopathological and Molecular Comparative Analysis. Modern Pathology, 2003, 16, 742-751.	5.5	96
48	A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. Journal of Nuclear Medicine, 2002, 43, 1482-8.	5.0	95
49	Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of <i>MED12</i> and <i>RBM10</i> as Novel Thyroid Cancer Genes Associated with Tumor Virulence. Clinical Cancer Research, 2017, 23, 5970-5980.	7.0	89
50	Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review. Radiotherapy and Oncology, 2011, 101, 425-430.	0.6	88
51	Detection of Tyrosinase mRNA by Reverse Transcription Polymerase Chain Reaction in Melanoma Sentinel Nodes. Annals of Surgical Oncology, 1999, 6, 232-240.	1.5	85
52	Frequent <i>IDH2</i> R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas. Journal of Pathology, 2017, 242, 400-408.	4.5	83
53	DNA methylation-based classification of sinonasal undifferentiated carcinoma. Modern Pathology, 2019, 32, 1447-1459.	5.5	82
54	Molecular, Morphologic, and Outcome Analysis of Thyroid Carcinomas According to Degree of Extrathyroid Extension. Thyroid, 2010, 20, 1085-1093.	4.5	80

#	Article	IF	CITATIONS
55	Clinical Significance of Molecular Expression Profiles of Hürthle Cell Tumors of the Thyroid Gland Analyzed via Tissue Microarrays. American Journal of Pathology, 2002, 160, 175-183.	3.8	79
56	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. Nature Communications, 2017, 8, 1197.	12.8	77
57	Immunohistochemical Detection of Mutated BRAF V600E Supports the Clonal Origin of BRAF-Induced Thyroid Cancers Along the Spectrum of Disease Progression. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1414-E1421.	3.6	76
58	Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6–NTRK3 fusion. Modern Pathology, 2016, 29, 985-995.	5.5	74
59	Hürthle cell carcinoma: A 60-year experience. Annals of Surgical Oncology, 2002, 9, 197-203.	1.5	73
60	Update to the College of American Pathologists Reporting on Thyroid Carcinomas. Head and Neck Pathology, 2009, 3, 86-93.	2.6	73
61	Patterns of recurrence in oral tongue cancer with perineural invasion. Head and Neck, 2018, 40, 1287-1295.	2.0	73
62	Factors Influencing the Basal and Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin in Patients with Metastatic Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 6010-6016.	3.6	72
63	Problems and Controversies in the Histopathology of Thyroid Carcinomas of Follicular Cell Origin. Archives of Pathology and Laboratory Medicine, 2009, 133, 683-691.	2.5	72
64	PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with <i>PLAG1</i> genetic abnormalities. Histopathology, 2018, 72, 285-293.	2.9	71
65	Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic) Tj ETQq1 1 0.784314	rgBT/Ove	erlock 10 Tf 5
66	Prognostic Factors in Myoepithelial Carcinoma of Salivary Glands. American Journal of Surgical Pathology, 2015, 39, 931-938.	3.7	68
67	Effective Intravenous Therapy of Murine Pulmonary Metastases with an Oncolytic Herpes Virus Expressing Interleukin 12. Clinical Cancer Research, 2004, 10, 251-259.	7.0	63
68	Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Research, 2018, 78, 4642-4657.	0.9	60
69	Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodineâ€refractory thyroid cancer. Cancer, 2017, 123, 4114-4121.	4.1	59
70	Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery, 2006, 140, 899-906.	1.9	58
71	Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell–derived thyroid carcinomas: a clinicopathologic study of 276 cases. Human Pathology, 2015, 46, 1789-1798.	2.0	58
72	The utility of p16 immunostaining in fine needle aspiration in p16-positive head and neck squamous cell carcinoma. Human Pathology, 2016, 54, 193-200.	2.0	57

#	Article	IF	CITATIONS
73	<i>EIF1AX</i> and <i>RAS</i> Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC. Cancer Discovery, 2019, 9, 264-281.	9.4	57
74	Panâ€Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting <i>ETV6</i> – <i>NTRK3</i> fusion. Histopathology, 2020, 76, 375-382.	2.9	57
75	SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. Cancer Discovery, 2021, 11, 1158-1175.	9.4	57
76	Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?. Endocrine, 2018, 59, 143-150.	2.3	57
77	International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. Journal of Clinical Oncology, 2022, 40, 96-104.	1.6	57
78	Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes. Thyroid, 2016, 26, 219-226.	4.5	56
79	Inter-Observer Variation in the Pathologic Identification of Minimal Extrathyroidal Extension in Papillary Thyroid Carcinoma. Thyroid, 2016, 26, 512-517.	4.5	56
80	Encapsulated Malignant Follicular Cell-Derived Thyroid Tumors. Endocrine Pathology, 2010, 21, 212-218.	9.0	54
81	Poorly Differentiated Thyroid Carcinoma Presenting with Gross Extrathyroidal Extension: 1986–2009 Memorial Sloan-Kettering Cancer Center Experience. Thyroid, 2013, 23, 997-1002.	4.5	54
82	Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell–Derived Thyroid Carcinomas. Thyroid, 2016, 26, 1588-1597.	4.5	53
83	Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics. Thyroid, 2017, 27, 632-640.	4.5	52
84	Prognostic Factors in Papillary Microcarcinoma with Emphasis on Histologic Subtyping: A Clinicopathologic Study of 148 Cases. Thyroid, 2014, 24, 245-253.	4.5	51
85	Salivary gland epithelial neoplasms in pediatric population: a single-institute experience with a focus on the histologic spectrum and clinical outcome. Human Pathology, 2017, 67, 37-44.	2.0	51
86	Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers. Journal of Clinical Investigation, 2018, 128, 4086-4097.	8.2	49
87	Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure. Thyroid, 2015, 25, 993-998.	4.5	46
88	Metastatic solid tumors to the jaw and oral soft tissue: A retrospective clinical analysis of 44 patients from a single institution. Journal of Cranio-Maxillo-Facial Surgery, 2016, 44, 1047-1053.	1.7	46
89	Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma?. Surgery, 2020, 167, 10-17.	1.9	46
90	Higher Administered Activities of Radioactive Iodine Are Associated with Less Structural Persistent Response in Older, but Not Younger, Papillary Thyroid Cancer Patients with Lateral Neck Lymph Node Metastases. Thyroid, 2014, 24, 1088-1095.	4.5	45

RONALD A GHOSSEIN

#	Article	IF	CITATIONS
91	The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Human Pathology, 2018, 74, 1-4.	2.0	45
92	Misinterpreted Myoepithelial Carcinoma of Salivary Cland. American Journal of Surgical Pathology, 2019, 43, 601-609.	3.7	44
93	Prognostic Value of Vascular Invasion in Well-Differentiated Papillary Thyroid Carcinoma. Thyroid, 2015, 25, 503-508.	4.5	43
94	The immune microenvironment and expression of PD‣1, PDâ€1, PRAME and MHC I in salivary duct carcinoma. Histopathology, 2019, 75, 672-682.	2.9	43
95	Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers. Nature Biomedical Engineering, 2020, 4, 272-285.	22.5	43
96	Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. Modern Pathology, 2020, 33, 1690-1701.	5.5	42
97	White adipose tissue inflammation and cancerâ€specific survival in patients with squamous cell carcinoma of the oral tongue. Cancer, 2016, 122, 3794-3802.	4.1	41
98	Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising from Follicular Cell–Derived Thyroid Cancer. Thyroid, 2016, 26, 518-524.	4.5	41
99	Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules. Surgery, 2019, 165, 17-24.	1.9	41
100	Primary highâ€grade nonâ€anaplastic thyroid carcinoma: a retrospective study of 364 cases. Histopathology, 2022, 80, 322-337.	2.9	41
101	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head and Neck, 2022, 44, 1277-1300.	2.0	41
102	Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG). American Journal of Surgical Pathology, 2020, 44, 545-552.	3.7	39
103	Primary squamous cell carcinoma within a solitary nonparasitic hepatic cyst. Journal of Surgical Oncology, 1994, 57, 210-212.	1.7	38
104	Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer. Clinical Cancer Research, 2020, 26, 3110-3116.	7.0	36
105	The prognostic role of histologic grade, worst pattern of invasion, and tumor budding in early oral tongue squamous cell carcinoma: a comparative study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 597-606.	2.8	36
106	Encapsulated Thyroid Carcinoma of Follicular Cell Origin. Endocrine Pathology, 2015, 26, 191-199.	9.0	35
107	Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features. Endocrine, 2019, 64, 97-108.	2.3	35
108	How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid, 2019, 29, 1792-1803.	4.5	33

#	Article	IF	CITATIONS
109	Pathologic Reporting of Tall-Cell Variant of Papillary Thyroid Cancer: Have We Reached a Consensus?. Thyroid, 2017, 27, 1498-1504.	4.5	32
110	Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management. European Journal of Surgical Oncology, 2018, 44, 338-347.	1.0	32
111	Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon. Human Pathology, 2017, 65, 133-139.	2.0	30
112	Enhancing Radioiodine Incorporation in <i>BRAF</i> -Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. Thyroid, 2022, 32, 273-282.	4.5	30
113	Histologic spectrum of polymorphous adenocarcinoma of the salivary gland harbor genetic alterations affecting PRKD genes. Modern Pathology, 2020, 33, 65-73.	5.5	29
114	Poorly differentiated thyroid carcinoma. Seminars in Diagnostic Pathology, 2020, 37, 243-247.	1.5	29
115	Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance. Human Pathology, 2019, 93, 30-36.	2.0	27
116	Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4889-4899.	3.6	26
117	Molecular detection and characterization of circulating tumor cells and micrometastases in prostatic, urothelial, and renal cell carcinomas. Journal of Surgical Oncology, 2001, 20, 304-311.	1.4	24
118	Detection and assessment of capsular invasion, vascular invasion and lymph node metastasis volume in thyroid carcinoma using microCT scanning of paraffin tissue blocks (3D whole block imaging): a proof of concept. Modern Pathology, 2020, 33, 2449-2457.	5.5	23
119	de Quervain's thyroiditis: A review of experience with surgery. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2016, 37, 534-537.	1.3	22
120	Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging. Thyroid, 2019, 29, 619-624.	4.5	22
121	The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma. Modern Pathology, 2019, 32, 205-215.	5.5	22
122	A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3618-3630.	6.4	21
123	Characterization of Subtypes of <i>BRAF</i> -Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1030-1039.	3.6	21
124	Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 110, 62-72.	2.0	20
125	Prophylactic Lateral Neck Dissection for Medullary Thyroid Carcinoma is not Associated with Improved Survival. Annals of Surgical Oncology, 2021, 28, 6572-6579.	1.5	18
126	Transposon mutagenesis identifies chromatin modifiers cooperating with <i>Ras</i> in thyroid tumorigenesis and detects <i>ATXN7</i> as a cancer gene. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4951-E4960.	7.1	17

#	Article	IF	CITATIONS
127	Crucial parameters in thyroid carcinoma reporting – challenges, controversies and clinical implications. Histopathology, 2018, 72, 32-39.	2.9	17
128	Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): An Update. Head and Neck Pathology, 2020, 14, 303-310.	2.6	17
129	Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes. Thyroid, 2022, 32, 245-254.	4.5	17
130	A proportion of primary squamous cell carcinomas of the parotid gland harbour highâ€risk human papillomavirus. Histopathology, 2016, 69, 921-929.	2.9	15
131	Fluorescence-guided resection of tumors in mouse models of oral cancer. Scientific Reports, 2020, 10, 11175.	3.3	15
132	Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hürthle cell carcinoma. Science Advances, 2022, 8, .	10.3	15
133	Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. Molecular Cancer Research, 2022, 20, 45-55.	3.4	13
134	Inter-Observer Variation in the Pathologic Identification of Extranodal Extension in Nodal Metastasis from Papillary Thyroid Carcinoma. Thyroid, 2016, 26, 816-819.	4.5	12
135	NRAS Q61R immunohistochemical staining in thyroid pathology: sensitivity, specificity and utility. Histopathology, 2021, 79, 650-660.	2.9	12
136	Clinicopathologic features and outcome of head and neck mucosal spindle cell squamous cell carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 729-739.	2.8	11
137	Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. Cancer, 1996, 78, 10-16.	4.1	10
138	The solid variant of papillary thyroid carcinoma: a multiâ€institutional retrospective study. Histopathology, 2022, 81, 171-182.	2.9	9
139	Undetectable Thyroglobulin Levels in Poorly Differentiated Thyroid Carcinoma Patients Free of Macroscopic Disease After Initial Treatment: Are They Useful?. Annals of Surgical Oncology, 2015, 22, 4193-4197.	1.5	8
140	Critical Prognostic Parameters in the Anatomic Pathology Reporting of Differentiated Follicular Cell-Derived Thyroid Carcinoma. Cancers, 2019, 11, 1100.	3.7	8
141	Solitary Extramedullary Plasmacytoma of the Cricoid Cartilage—Case Report. Frontiers in Oncology, 2017, 7, 284.	2.8	7
142	Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma. Annals of Surgical Oncology, 2019, 26, 4423-4429.	1.5	6
143	Depth of invasion versus tumour thickness in early oral tongue squamous cell carcinoma: which measurement is the most practical and predictive of outcome?. Histopathology, 2021, 79, 325-337.	2.9	6
144	Recurrent Differentiated Thyroid Carcinoma: Biological Implications of Age, Method of Detection, and Site and Extent of Recurrence. Annals of Surgical Oncology, 2002, 9, 789-798.	1.5	6

RONALD A GHOSSEIN

#	Article	IF	CITATIONS
145	Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity. Molecular Cancer Therapeutics, 2022, 21, 382-394.	4.1	6
146	Primary Mesenchymal Tumors of the Thyroid Gland: A Modern Retrospective Cohort Including the First Case of TFE3-Translocated Malignant Perivascular Epithelioid Cell Tumor (PEComa). Head and Neck Pathology, 2022, , 1.	2.6	6
147	The contribution of molecular pathology to the classification of thyroid tumors. Diagnostic Histopathology, 2018, 24, 87-94.	0.4	5
148	Nodal characteristics associated with adverse prognosis in oral cavity cancer are linked to host immune status. Journal of Surgical Oncology, 2021, 123, 141-148.	1.7	5
149	Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer. Cancer, 2019, 125, 2984-2990.	4.1	4
150	Histologic evaluation of host immune microenvironment and its prognostic significance in oral tongue squamous cell carcinoma: a comparative study on lymphocytic host response (LHR) and tumor infiltrating lymphocytes (TILs). Pathology Research and Practice, 2021, 228, 153473.	2.3	4
151	A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. Thyroid, 2022, 32, 799-806.	4.5	4
152	Diagnostic discrepancy in second opinion reviews of primary epithelial neoplasms involving salivary gland: An 11â€year experience from a tertiary referral center focusing on useful pathologic approaches and potential clinical impacts. Head and Neck, 2021, 43, 2497-2509.	2.0	2
153	HPVâ€related head and neck cancers: Pathology and biology. Journal of Surgical Oncology, 2021, 124, 923-930.	1.7	2
154	Recipient of the 2021 Endocrine Pathology Society Lifetime Achievement Award: Dr. Ronald A. DeLellis. Endocrine Pathology, 2021, 32, 429-431.	9.0	2
155	Lymphovascular invasion and active surveillance in thyroid cancer. European Journal of Surgical Oncology, 2020, 46, 1775-1776.	1.0	Ο
156	Hurthle Cell Adenoma and Carcinoma. , 2011, , 1764-1766.		0
157	Hurthle Cell Adenoma and Carcinoma. , 2014, , 1-3.		0
158	Hurthle Cell Adenoma and Carcinoma. , 2017, , 2157-2159.		0

Hurthle Cell Adenoma and Carcinoma. , 2017, , 2157-2159. 158